Skip to content

Calcium-phosphate Complications Induced by IV Iron Supplementation in Patients With Rendu-Osler Disease

Study of Calcium-phosphate Complications Induced by the Administration of IV Iron Supplementation in Patients With Rendu-Osler Disease

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05544669
Acronym
OS-LERETRO
Enrollment
220
Registered
2022-09-16
Start date
2022-08-01
Completion date
2024-07-21
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rendu Osler Disease

Keywords

Rendu-Osler disease, Hypophosphatemia, Injectable iron, Osteomalacia, Carbohydrates, Iron deficiency

Brief summary

Hypophosphatemia induced by treatments with injectable iron is a frequent side effect already reported during marketing. Situations of osteomalacia secondary to these hypophosphatemias are rarer and reported in the form of case reports in the literature. Hypophosphatemia in this context is attributed to an excess of FGF-23 (defect of degradation linked to carbohydrates in martial preparations) with renal leakage of phosphate. Rendu-Osler disease (ROM) is an autosomal dominant genetic disease, favoring the formation of vascular malformations, including nasal and digestive telangiectasias causing repeated bleeding, even hemorrhages. Iron deficiency is frequent and profound there, and oral martial treatments are often insufficient to compensate for these losses. Regular iron infusions, to avoid transfusions, are often necessary.

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Major subject (≥ 18 years old) * suffering from Rendu-Osler disease and receiving IV iron supplementation * Subject not objecting, after information, to the reuse of their data for scientific research purposes

Exclusion criteria

* Subject who expressed their opposition to participating in the study * Subject under safeguard of justice * Subject under guardianship or curatorship

Design outcomes

Primary

MeasureTime frame
Occurrence of a bone crack and/or fractureFiles analysed retrospectively from January 01, 2018 to December 31, 2022 will be examined

Countries

France

Contacts

Primary ContactMurielle RONDEAU-LUTZ, MD
murielle.rondeau-lutz@chru-strasbourg.fr33 3 69 55 10 13

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026